These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [General and specific laboratory parameters within the scope of tumor after-care in gynecologic malignancies and breast cancer]. Kreienberg R Gynakologe; 1989 Feb; 22(1):55-62. PubMed ID: 2653979 [No Abstract] [Full Text] [Related]
23. A comparative study of four serological tumor markers for the detection of breast cancer. Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928 [TBL] [Abstract][Full Text] [Related]
24. [The existence of a correlation between the serum values of MCA and CA 15.3 in patients with digestive tumors]. Roiz MC; Vizoso F; Allende MT; Ruibal A Rev Clin Esp; 1990 Nov; 187(7):376. PubMed ID: 2091127 [No Abstract] [Full Text] [Related]
25. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K]. Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444 [TBL] [Abstract][Full Text] [Related]
26. A new tumor marker MCA in breast cancer diagnosis. Eskelinen M; Tikanoja S; Collan Y Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156 [TBL] [Abstract][Full Text] [Related]
27. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer]. Bartel U; Johannsen B; Reiss H; Elling D Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715 [TBL] [Abstract][Full Text] [Related]
28. Serological tumor markers for monitoring breast cancer. Sölétormos G Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127 [No Abstract] [Full Text] [Related]
29. [The diagnostic value of the tumor markers CEA, "Ca 19-9", "Ca 125", "Ca15-3" and "SCC" for the detection of recurrent tumors in patients with tumors of the head and neck]. Zöller J; Fiehn W; Mende U; Hotz G Dtsch Z Mund Kiefer Gesichtschir; 1990; 14(4):254-9. PubMed ID: 2134649 [TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
31. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB J BUON; 2007; 12(4):487-92. PubMed ID: 18067207 [TBL] [Abstract][Full Text] [Related]
32. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer. Heinze T; Lichtenegger W Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666 [TBL] [Abstract][Full Text] [Related]
33. MCA performance in preoperative breast cancer patients. Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034 [TBL] [Abstract][Full Text] [Related]
34. [Immunologic tumor diagnosis]. Schmolke B Z Lymphol; 1990 Dec; 14(2):58-61. PubMed ID: 2087871 [TBL] [Abstract][Full Text] [Related]
35. BCM-IMx and CA15.3 serum levels in patients with breast cancer: a comparative study. Allende MT; Fernández Llana B; Rodriguez Alvarez JM; Roiz MC; Vizoso F; Ruibal A Bull Cancer; 1991; 78(8):743-5. PubMed ID: 1932840 [No Abstract] [Full Text] [Related]
36. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3. Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129 [TBL] [Abstract][Full Text] [Related]
37. High BCM serum levels in patients with non breast tumors: first results. Allende T; Vizoso F; Roiz C; Fueyo A; Lennartz L; Ruibal A Bull Cancer; 1990; 77(10):1031-2. PubMed ID: 2249013 [No Abstract] [Full Text] [Related]
38. [Clinical usefulness of tumor markers in breast cancer]. Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [TBL] [Abstract][Full Text] [Related]
39. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407 [TBL] [Abstract][Full Text] [Related]
40. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma]. Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]